Wednesday, 14 February 2018 16:02

Disclaimer on NAFDAC Recruitment!

NAFDAC hereby alerts the General public particularly the prospective applicants about the false and misleading post of a recruitment exercise by the Agency on a faceless and fake website.

Please Note:

The public is advised to note that information on any future recruitment exercise by NAFDAC would be posted on the official website of the agency; and other social media platforms of the agency and National dailies.

NAFDAC will not use any third party individuals, websites or other platforms to advertise positions or source for applicants.


The National Agency for Food and Drug Administration and Control (NAFDAC) has been alerted by the World Health Organization (WHO) on the circulation of two versions of falsified Cefixime products in the eastern part of the Democratic Republic of Congo (South Kivu).

The two versions of falsified Cefixime products were identified and reported to the World Health Organization in late 2017. Both products are presented in standard white plastic containers of 100 tablets. The label of both products display spelling mistakes.

The tablets of both products are round, small and without any embossing.

Cefixime is an antibiotic used to treat a range of bacterial infections. Treatment with ineffective falsified Cefixime tablets can lead to emergence of resistant organisms. In extreme cases, the use of falsified Cefixime tablets may result in death.

The details of the two versions of falsified Cefixime product are listed below:

Information on: Version 1 Version 2
Product Name Cefixime Cefixime trihydrate
Batch Number 4734 Et078776
Expiry Date 01/2016 Nov 2014
Declared active ingredient Cefixime Cifixime trihydrate
Stated manufacturer Merck & Co Inc Holden Medical The Netherlands
Assay testing results 2.5% of Cefixime No Cefixime detected

It should be noted that the manufacturers stated on the label have confirmed that they did not manufacture these products.

NAFDAC implores wholesalers, distributors, pharmacies, healthcare providers, proprietors of healthcare facilities, program managers and other members of the public to be vigilant and report anybody or organization distributing falsified Cefixime tablets to the nearest NAFDAC office.

If you are in possession of falsified Cefixime products, do not use or sell. Submit the falsified products to the nearest NAFDAC office.

Adverse events resulting from use of the falsified versions of Cefixime tablets should be reported to the nearest NAFDAC office, NAFDAC PRASCOR (20543 TOLL FREE from all networks) or via This email address is being protected from spambots. You need JavaScript enabled to view it. .

NAFDAC............Safeguarding the Health of the Nation!!!

National Agency for Food and Drug Administration and Control, NAFDAC has destroyed counterfeit drugs and other substandard regulated products worth over N80 Million in Abuja.

Director General of NAFDAC, Prof. Christianah Adeyeye who carried out the destruction exercise in company of other dignitaries said the offending products were mopped up from circulation through enforcement activities by the agency in Abuja and its environs while others were voluntarily forfeited by companies.

She stated that NAFDAC is continuously waging war against counterfeiting of regulated products even as she maintained that the destruction exercise was part of efforts to rid the country of this menace.

Her words: “This periodic exercise further gives credence to the fact that NAFDAC is continuously waging war against counterfeiting and faking of regulated products. We will continue to work relentlessly to ensure that this incidence is reduced to the barest minimum and only safe, efficacious and wholesome regulated products are available to the populace”.


While acknowledging the daunting challenges being faced by the agency in her surveillance and enforcement activities as a result of evolving strategies by violators to avoid arrest or prosecution, Prof. Adeyeye said NAFDAC is on top of the situation by deploying counter strategies to checkmate them and ensure they are brought to justice.


The new Director General, National Agency for Food and Drug Administration and Control (NAFDAC), Professor Mojisola Christianah Adeyeye has officially resumed duties with a commitment to lead the Agency toward eliminating substandard foods and drugs in the country.

Professor Adeyeye who disclosed this in Abuja at the Agency’s corporate headquarters while addressing staff on her resumption of duty, said although NAFDAC has over the years, made steady progress in protecting the health of the nation, the Agency under her administration will continue to ensure the health of all Nigerians and foreigners residing in Nigeria are not jeopardized by the use of substandard or counterfeit regulated products.

She expressed deep concern that while majority of Nigerians have concerns over safety of drugs, food, medical devices and water, little do they know that chemicals can also kill people easily, which is why she has come to ensure that NAFDAC lives up to her responsibility of eliminating falsified and unsafe drugs, medical devices, foods and water in Nigeria.


 “The concerns of our people are mainly about safety of our drugs, food, medical devices and water. Most people, including those who manufacture fake drugs and sell bad foods or water, do not plan to kill people, but may not fully understand that chemicals (be they in drugs or food, or through bio-contamination) can kill hundreds of people easily”.

The NAFDAC DG expressed appreciation to the United States Pharmacopeia (USP); United States Agency for International Development (USAID); World Health Organisation (WHO); Nigeria Academic Pharmacists as well as other partners for their efforts and support of NAFDAC in the assurance of quality food, medicines and medical devices for all Nigerians.

She equally thanked the National assembly for their efforts so far towards passing the Fake and Counterfeit Drug Act, saying the attainment of the mission and vision of NAFDAC is a collective responsibility of all and her role as a Director General is to provide the needed leadership, direction and motivation to all staff for the realization of the goals of the Agency.

handover2L-R: Dr. Abubakar Jimoh, Director Special Duties NAFDAC, Prof. Mojisola Christianah Adeyeye, Director-General, NAFDAC, Mr. Ademola Mogbojuri, the immediate past Ag. DG, NAFDAC, Dr Monica Eimunjeze, Director Drug Evaluation and Research and Prof. Samson Adebayo, Director Planning, Research and Statistics during the hand-over ceremony in Abuja.

Earlier addressing Management staff during a brief handover, Professor Adeyeye acknowledged that though NAFDAC will be taking a new path, with all hands on deck, they can achieve greater success. “We are all going there together because of our children, our husbands, our wives and indeed every Nigerian. We are in charge of food, drug and water. That is to say anything that goes into our body, we are in charge of it and that is how serious I take drugs, food and water and we will go there together”.

She maintained that there is so much responsibility for NAFDAC as an Agency of government in terms of preventing adulterated and substandard drugs, food and water which can cause death and she is determined to ensure the workforce is strong and highly motivated to achieve the Agency’s mandate.

In his remark, immediate past Acting Director General of NAFDAC, Mr. Ademola Mogbojuri expressed delight that the Agency has yet another professor per excellence to take over the baton of leadership in NAFDAC, saying it is a new dawn all hands must be on deck to take the Agency to a lofty height where it can remain a reference point in the comity of regulatory agencies in the country.

Dr. Abubakar Jimoh

Director Special Duties


This year, World Antibiotic Awareness Week will be held from 13 to 19 November 2017. The theme: Seek advice from a qualified healthcare professional before taking antibiotics. WHO encourages countries, partners, and the public to join this campaign and help raise awareness of antibiotic resistance

Monday, 18 September 2017 10:15

Singapore Recalls Faulty HIV Test Kits

The National Agency for Food and Drug Administration and Control has been informed that the Singapore's Health Sciences Authority (HSA), on 6th June, drew the attention of individual to the recall of a brand of test kit, SD Bioline HIV Ag/Ab combo kits.

The HSA stated that it was notified by a Singaporean importer, Unison Collaborative, that nine (9) lots of the kits were recalled by the Korea based manufacturer, Standard Diagnostic Inc. due to their reduced sensitivity. According to the manufacturer, when a patient is in the early window period, the lower sensitivity of the affected lots may reduce detection with the possibility of a false negative result for this subset of patients.

The HSA informed that the SD Bioline HIV Ag/Ab Combo Assay test kit may be unable to detect the infection in the blood during the early stages of HIV infection.

Further information shows that five hundred and eighty four (584) of the SD Bioline HIV Ag/Ab combo kits were supplied to 27 healthcare facilities and 26 clinics and one general hospital in Singapore.

The details of the products are as follows:

BRAND NAME:         SD Bioline HIV Ag/Ab combo kits.

MANUFACTURER: Standard diagnostic Inc. South Korea

LOT NUMBER:               All lots from February, 2016 up to May, 2017

Healthcare Provider’s Action.

  • Healthcare providers in possession of these affected products should stop using them and submit them to the nearest NAFDAC office.
  • Healthcare providers and patients are encouraged to report adverse events associated with the use of these products to the nearest NAFDAC office, NAFDAC PRASCOR (20543 TOLL FREE from all networks) or via This email address is being protected from spambots. You need JavaScript enabled to view it.

NAFDAC............Safeguarding the Health of the Nation!!!

The National Agency for Food and Drug Administration and Control (NAFDAC) has been informed that the Bureau of Standard Jamaica, on 25th May, 2017 banned the importation of L.A. Lucky brand Sweet Basil seed into the island.      The product is produced by 3 Dolphins wholesale; 4801 Victoria Drive, Vancouver, British Columbia Canada.

The potential contamination was noted after routine testing by the company revealed presence of Salmonella in some lot of 2.1ounce of the product.

Salmonella is an organism which can cause serious and sometimes fatal infection in young children or elderly people, and others with weakened immune system.

Details of Affected Products.

L.A LUCKY SWEET BASIL SEED  20678 201697 60g All units sold from October, 2015 up to May, 25th 2017. 2.1 ounce, clear plastic package

v  All outlets and consumers with these products should immediately stop their sale and use.The affected product should be submitted to the nearest NAFDAC office for appropriate action. Importers are advised not to import affected product.

NAFDAC..........Safeguarding the health of the nation!!!

The Agency have been notified by the U.S. Food and Drug Administration of its restriction of codeine and tramadol medicines use in children younger than 12 years.

Codeine is approved to treat pain and cough, and tramadol is approved to treat pain.

These medicines have been found to be capable of posing serious health risks including slowed or difficult breathing condition and death in children younger than 12 years.

Single ingredient codeine and all tramadol containing products are FDA approved only for use in adults. FDA is also recommending against the use in breastfeeding mothers due to possible harm to their infants.

The U.S. FDA is also requiring several changes to labels of all prescription medicines containing codeine and tramadol indicating the following;

  • Codeine should not be used to treat pain or cough and tramadol should not be used to treat pain in children younger than 12 years.
  • Tramadol should not be used in children younger than 18 years to treat pain after surgery to remove the tonsil and/or adenoids.
  • Recommend against use of tramadol and codeine in adolescents between 12 and 18 years who are obese or have conditions such as obstructive sleep apnea or severe lung disease, which may increase the risk of serious breathing problems.
  • Codeine and tramadol use in breastfeeding mothers is not recommended due to risk of serious health hazards to the breastfed infants, such as excess sleepiness, difficulty breastfeeding, or serious breathing problem that could result to deaths.

Healthcare Provider Action

  • Recommend over-the-counter (OTC) or other approved prescription medicines for cough and pain management in children younger than 12 years and adolescents younger than 18 years especially those with certain genetic factors, obesity, or obstruction sleep apnea and other breathing problems.
  • Healthcare providers and patients should always lookout for tramadol or codeine on labels of prescription bottles.
  • Watch out for signs of breathing problems, slow or shallow breathing, difficulty or noisy breathing, unusual sleepiness and trouble breastfeeding.
  • Report adverse events relating to use of these medicines to NAFDAC PRASCOR (20543-Toll free from all networks) or via This email address is being protected from spambots. You need JavaScript enabled to view it.

NAFDAC.........Safeguarding the Health of the Nation!!!

The National Agency for Food and Drug Administration and Control (NAFDAC) has been notified of the circulation of two confirmed falsified Quinine Sulphate 300mg tablet versions in Cameroon and the Democratic Republic of Congo.  The products have been found to contain zero active pharmaceutical ingredients.

Quinine Sulphate is an anti-malaria drug used for the treatment of Plasmodium falciparum Malaria. These falsified products were first discovered by a local NGO on failing field screening. They were submitted to a WHO pre-qualified Quality Assurance Laboratory and subsequent analysis from the laboratory showed neither of the products contained any of the stated active ingredients.

The details of the falsified products are;

Product 1 Product 2

Product Name: Quinine Sulphate 300mg

Manufacturer: Novadina Pharmaceutical Ltd,  

                            London, United Kingdom

Number of tablets per container: 1000

Batch Number: 10H05

Date of Manufacture:  09/2014

Expiry date: 09/2018

Product Name: Quinine Sulphate 300mg

Manufacturer: CAD Pharm, India

Number of tablets per container: 100

Batch Number: F4387

Date of Manufacture:  12/14

Expiry date: 11/18

NAFDAC implores importers, distributors, retailers and the general public to ensure vigilance and avoid the purchase of the confirmed falsified products.

 All distributors, retailers and members of the public with these falsified products should submit products to the nearest NAFDAC office for distruction.

NAFDAC...........Safeguarding the health of the Nation!!!

Fundamentals of Biostatistics in Evidence-Driven Regulatory Decision Making came up partly as an off-shoot of the National Agency for Food and Drug Administration and Control mentorship with Health Canada; and on the other hand as part of the Director General’s vision for NAFDAC to constantly ensure an Evidence-Driven Regulatory Decision Making.

This Biostatistics workshop came up as one of the series of such planned for the Agency’s 2014 Workplan. Again, in line with the recommendation of the Steering Committee working on the Action Plan of the Health Canada-NAFDAC Regulatory Capacity Mentorship Program; this workshop came up on the 6th and 7th March, 2014 at the NAFDAC’s Central Laboratory Auditorium located at Oshodi, Lagos.

The workshop was well attended by the members of the Steering Committee and other staff of the Agency from various Directorates. More importantly, the Director General, Dr. Paul Botwev Orhii OON; also graced the occasion.

Two renowned Professors of Biostatistics from the University College Hospital and University of Ilorin joined forces with Dr. Samson B. Adebayo, the Director of Planning, Research and Statistics (PR&S) and Dr Monica H. Eimunjeze, the Director of Registration and Regulatory (R&R) to deliver high quality Lectures. The workshop took the participants through both classroom lectures and hands-on practical sessions on the use of a Statistical Package for Social Scientists (SPSS) to analyse related datasets from the Agency.

The Director General in his remark, welcomed and appreciated the Director (R&R) and Director (PR&S) for coming up with such a wonderful workshop and further stated that such workshop is long overdue for the status of the Agency. He also appreciated all the facilitators and the staff that attended the workshop.

The Director of R&R, Dr Monica H. Eimunjeze appreciated all staff that attended the workshop and advised them to make good use of the opportunity to enhance their performance and better their output in their respective Directorates.

Dr Samson B. Adebayo, the Director of Planning, Research and Statistics who anchored the workshop encouraged all the participants to put into use; the skills that will be acquired at the workshop. In the opening session, he emphasised how important roles of Biostatistics are in ensuring Evidence-Driven Regulatory Decision Making.

Event picture Gallery:

Click link to view more event pictures

  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  Next 
  •  End 
Page 1 of 2



Contact Us from Mon - Friday: 08:00-16:00 GMT+1

Write Us:

NAFDAC Corporate Headquarters,

Plot 2032, Olusegun, Obasanjo Way,

Zone 7, Wuse, Abuja, Nigeria


Lagos Operation Office:

Plot 1, Industrial Estate, Lagos- Oshodi Apapa Express Way, Isolo, Lagos, Nigeria







For Enquiries:

Call: +234(0)-1-4609750












For Complaints:

Call: +234(0)909-763-0506


Or Send Us a Complaint










Contact Other NAFDAC Offices Nationwide